“This bill maximizes the nation’s investment in basic research, and helps boost U.S. competitiveness, creates jobs and spurs new business and industries,” said Representative Lamar Smith (R–TX), who chairs the House science committee, in a statement issued shortly after the vote. “It improves accountability and transparency, reduces administrative burden on researchers, enhances agency oversight, which improves research coordination, and reforms federal science agency programs to increase the impact of taxpayer-funded research.”
China and other Asian nations have vaulted past the United States to the forefront of the global clean-energy technology market, according to a new report from the Information Technology and Innovation Foundation (ITIF).
Federal departments and agencies, including the science agencies and programs, will now face uncertainty about the total funds they have to spend for the upcoming year. They will likely respond by spending conservatively in the first months of 2017 as a precaution. In addition, they will be barred from starting new programs or stopping old ones and from implementing funding increases submitted in the president’s fiscal year 2017 budget request.
The U.S. remains a powerhouse of research and development. As the National Science Foundation reported in September, total national R&D funding from all sources reached nearly $500 billion in 2015, more than any nation has ever spent on it in one year. The share supplied by industry also reached a record-high 69%. This is excellent news.
Congress passed sweeping legislation Wednesday that boosts funding for medical research, eases the development and approval of experimental treatments and reforms federal policy on mental health care. The 94 to 5 Senate vote Wednesday followed a 392 to 26 House vote last week.
Congress has reached a truce -- and possibly a lasting settlement -- in the fiercely partisan 3-year war between Republican leaders in the House of Representatives and the scientific community over how the National Science Foundation (NSF) should operate. The terms of the agreement, between House and Senate negotiators, may seem like minor changes. But the compromise, which the Senate could adopt as early as this week, resolves differences over how NSF should conduct peer review and manage research in ways that the agency thinks it can live with.
The House on Wednesday passed a medical innovation bill aimed at curing diseases, with the measure securing bipartisan support after months of negotiations. The legislation, known as the 21st Century Cures Act, passed 392-26. It seeks to speed up the Food and Drug Administration’s approval of new drugs while investing new money in medical research.
Congress is poised to approve a massive piece of legislation that would provide the National Institutes of Health (NIH) with $4.8 billion over the next decade for a set of research initiatives, including brain and cancer research and efforts to develop so-called precision medicine treatments that are tailored to an individual’s genetic makeup.
This is a special time for technology. Five of the world’s seven most valuable companies are U.S. tech firms. But the core innovations underlying Apple Inc., Alphabet Inc., Microsoft Corp., Amazon.com Inc. and Facebook Inc. are decades old.
Federal funding for research at higher education institutions declined for a fourth straight year, according to a new report from the National Center for Science and Engineering Statistics (NCSES). During a peak in Fiscal Year (FY) 2011, federal funding accounted for 62.5 percent of total higher education research and development (R&D) expenditures.